Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

at could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than we or others do, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... Nov. 24, 2014  AiCure, an artificial intelligence ... to monitor medication ingestion, has announced the start ... intervene with patients receiving medication as maintenance therapy ... from prescription opiates have quadrupled in the last ... year than heroin, cocaine and benzodiazepines combined. Overall, ...
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... devices worldwide, today announced that it will take part in ... held between November 16 and 19 in Dusseldorf, Germany. Mindray ... the 43rd World Forum of Medicine - International Trade Fair ...
... N.J., Nov. 4, 2011 Pharmasset, Inc. (Nasdaq: ... BMY ) announced today the addition of four ... the combination of Pharmasset,s PSI-7977, a nucleotide polymerase inhibitor, ... replication complex inhibitor, for the treatment of chronic hepatitis ...
Cached Medicine Technology:Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 2Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011 3New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1 2New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1 3New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1 4New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1 5
(Date:11/24/2014)... "My friend was killed when a vehicle ... street in his motorized wheelchair," said an inventor from ... up with this idea so that people in wheelchairs ... the Safety Lites to make a wheelchair highly visible, ... ensures that motorists can see the wheelchair. This helps ...
(Date:11/23/2014)... the coming special Friday, Tidebuy, a famous wedding dress ... many products, especially the beautiful colored wedding dresses ( ... amazing discounts, up to 90% off. Don’t hesitate to ... to buy colored wedding dresses in different sizes and ... for delicate craftsmanship, elegant style and perfect lines. All ...
(Date:11/23/2014)... Vancouver, BC (PRWEB) November 23, 2014 Pro ... recently announced that it will now be providing an 8 ... number of hot water tank installations went up due to ... Care to assure its customers of the premium service that ... be offering 8 year warranty on John Wood and Bradford ...
(Date:11/23/2014)... -- The holidays can be a challenge for families ... major meltdowns, an expert says. "Holidays with family ... when you have children with special needs, some care ... at University of the Sciences in Philadelphia, said in ... your hosts or visitors know what special requirements are ...
(Date:11/23/2014)... To show thanks to new and old customers, ... evening dresses for weddings. Customers who need custom outfits ... a distinguished dress manufacturer, and it is among the ones ... a very long time. The CEO of this company says, ... able to buy not only a beautiful dress, but also ...
Breaking Medicine News(10 mins):Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... to reduce greenhouse gas emissions, New Mexico could experience ... by wildfires and health-care. This could translate to an ... income by 2020, according to a report produced for ... Climate Economics by ECONorthwest. , In addition, the report ...
... Technology for Patients and FamiliesWASHINGTON, Feb. 18 ... American women are living with or are at ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090218/DC72747LOGO-b )With coronary heart ... over the age of 50, the Society for ...
... Center and Duke University Medical Center have linked mutations in ... of the most common types of brain cancers known as ... carry these genetic alterations appear to survive at least twice ... the genes could also lead to more precise diagnosis and ...
... 19, 2009 at 10:30 am PT MISSION VIEJO, Calif., ... ENSG ), the parent company of the Ensign(TM) group of ... reported record results for the fourth quarter of fiscal year ... Include: , , , ...
... , , WEDNESDAY, Feb. 18 (HealthDay News) -- Researchers report that ... in the development of some particularly dangerous types of brain ... better treatments for one of the most deadly forms of ... published in the Feb. 19 issue of the New ...
... papillomavirus (HPV) is a group of viruses that includes more ... common sexually transmitted virus. The American Social Health Association (ASHA) ... will contract HPV sometime in their lives. HPV is most ... did you know HPV also causes oral cancer? , According ...
Cached Medicine News:Health News:What if New Mexico doesn't address climate change? 2Health News:What if New Mexico doesn't address climate change? 3Health News:What if New Mexico doesn't address climate change? 4Health News:Society for Women's Health Research and MITA Promote Greater Awareness of Medical Imaging to Diagnose Women's Coronary Artery Disease 2Health News:Society for Women's Health Research and MITA Promote Greater Awareness of Medical Imaging to Diagnose Women's Coronary Artery Disease 3Health News:Society for Women's Health Research and MITA Promote Greater Awareness of Medical Imaging to Diagnose Women's Coronary Artery Disease 4Health News:2 gene mutations linked to most common brain cancers -- and longer survival 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 3Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 4Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 5Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 6Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 7Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 8Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 9Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 10Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 11Health News:Genetic Mutations Linked to Deadly Brain Cancer 2Health News:Human papillomavirus lesion identified at the dentist 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: